

# Mohamad Shebley, Fcp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2465294/publications.pdf>

Version: 2024-02-01

29  
papers

820  
citations

687220

13  
h-index

501076

28  
g-index

30  
all docs

30  
docs citations

30  
times ranked

972  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Elagolix on the Pharmacokinetics of Omeprazole and its Metabolites in Healthy Premenopausal Women. <i>Clinical and Translational Science</i> , 2022, , .	1.5	1
2	Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids. <i>Clinical Pharmacokinetics</i> , 2022, 61, 577-587.	1.6	2
3	Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure. <i>Biopharmaceutics and Drug Disposition</i> , 2022, 43, 98-107.	1.1	4
4	Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 297-310.	2.3	63
5	Drug-Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy. <i>Clinical Pharmacokinetics</i> , 2021, 60, 133-143.	1.6	8
6	Mechanistic Modeling of Intra-Tumor Spatial Distribution of Antibody-Drug Conjugates: Insights into Dosing Strategies in Oncology. <i>Clinical and Translational Science</i> , 2021, 14, 395-404.	1.5	8
7	A Personalized Medicine Approach Using Clinical Utility Index and Exposure-Response Modeling Informed by Patient Preferences Data. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 40-47.	1.3	2
8	Integrating real-world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women. <i>Clinical and Translational Science</i> , 2021, 14, 1452-1463.	1.5	5
9	Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis. <i>Clinical and Translational Science</i> , 2021, 14, 1611-1619.	1.5	3
10	Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2020, 59, 617-627.	1.6	17
11	Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. <i>Clinical Pharmacokinetics</i> , 2020, 59, 297-309.	1.6	44
12	Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1606-1616.	1.0	10
13	Practical Assessment of Clinical Drug-Drug Interactions in Drug Development Using Physiologically Based Pharmacokinetics Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1326-1328.	2.3	3
14	Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 625-637.	1.0	10
15	Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 320-321.	2.3	2
16	Industry Perspective on Standardizing Food-Effect Studies for New Drug Development. <i>Clinical Pharmacokinetics</i> , 2018, 57, 901-909.	1.6	3
17	Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. <i>Future Oncology</i> , 2018, 14, 2115-2129.	1.1	47
18	Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 443-456.	0.8	17

#	ARTICLE	IF	CITATIONS
19	Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 88-110.	2.3	254
20	Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 679-687.	2.3	28
21	Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir. <i>Drug Metabolism and Disposition</i> , 2017, 45, 755-764.	1.7	35
22	Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 796-804.	1.0	52
23	Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4926-4947.	2.9	26
24	Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group--An Industry Perspective. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1720-1730.	1.7	39
25	Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 179-188.	2.3	76
26	Mechanistic Analysis of the Inactivation of Cytochrome P450 2B6 by Phencyclidine: Effects on Substrate Binding, Electron Transfer, and Uncoupling. <i>Drug Metabolism and Disposition</i> , 2009, 37, 745-752.	1.7	11
27	Mutation of a Single Residue (K262R) in P450 2B6 Leads to Loss of Mechanism-Based Inactivation by Phencyclidine. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1365-1371.	1.7	13
28	SELECTIVE PATHWAYS FOR THE METABOLISM OF PHENCYCLIDINE BY CYTOCHROME P450 2B ENZYMES: IDENTIFICATION OF ELECTROPHILIC METABOLITES, GLUTATHIONE, AND N-ACETYL CYSTEINE ADDUCTS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 375-383.	1.7	31
29	Interdisciplinary Model-Informed Drug Development for Extending Duration of Elagolix Treatment in Patients with Uterine Fibroids. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	4